Objective: To describe outcomes of HIV-infected pediatric patients with drug-resistant tuberculosis (DR TB). Methods: Demographic, clinical and laboratory data from charts of pediatric patients treated for DR TB during [2005][2006][2007][2008] were collected retrospectively from 5 multi-DR TB hospitals in South Africa. Data were summarized, and Pearson χ 2 test or Fisher exact test was used to assess differences in variables of interest by HIV status. A time-to-event analysis was conducted using days from start of treatment to death. Variables of interest were first assessed using the Kaplan-Meier method. Cox proportional hazard models were fit to estimate crude and adjusted hazard ratios. Results: Of 423 eligible participants, 398 (95%) had culture-confirmed DR TB and 238 (56%) were HIV infected. A total of 54% were underweight, 42% were male and median age was 10.7 years (interquartile range: 5.5-15.3). Of the 423 participants, 245 (58%) were successfully treated, 69 (16%) died, treatment failed in 3 (1%), 36 (9%) were lost to follow-up and 70 (17%) were still on treatment, transferred or had unknown outcomes. Time to death differed by HIV status (P = 0.008), sex (P < 0.001), year of tuberculosis diagnosis (P = 0.05) and weight status (P = 0.002). Over the 2-year risk period, the adjusted rate of death was 2-fold higher among participants with HIV compared with HIV-negative participants (adjusted hazard ratio = 2.28; 95% confidence interval: 1.11-4.68). Conclusions: Male, underweight and HIV-infected children with DR TB were more likely to experience death when compared with other children with DR TB within this study population.
I n 2015, there were an estimated 480,000 new cases of multidrugresistant tuberculosis (MDR TB), defined as tuberculosis (TB) having resistance to at least isoniazid (INH) and rifampicin. 1, 2 An estimated 1 million children develop TB each year. 1 Pediatric TB results from recent transmission (as opposed to reactivation), especially in young children. [3] [4] [5] [6] [7] Attempts to quantify the incidence of MDR TB in children estimate that 3.2% of new pediatric TB cases are MDR TB and indicate that the risk of MDR TB is generally similar among children and adults. 3, 8 As expected, estimates of drug resistance in children are often higher in high-burden countries. In South Africa, it is estimated that 15% of pediatric patients with culture-confirmed TB have a strain resistant to INH and 8.9% have MDR TB similar to adults. 1, 7, [9] [10] [11] Approximately 12% of the 9.6 million incident cases of TB around the world in 2014 were also infected with HIV. 1 South Africa has one of the highest burdens of HIV-infected TB cases worldwide. In 2014, 61% of incident TB cases in South Africa were also infected with HIV. 1 HIV-infected TB cases present additional challenges in treating DR TB and are associated with worse treatment outcomes and survival. [12] [13] [14] [15] [16] In South Africa, data from a variety of cross-sectional studies indicate that 11%-64% of children with TB are HIV infected. 17 Although there is conflicting evidence about the association between HIV infection and DR TB, 7, 18, 19 once infected with TB, children who are younger or HIV infected are more likely to progress to TB disease. 20 In South Africa, each adult with MDR TB has, on average, nearly 2 contacts who are younger than 5 years. 4 Outcomes and survival in adults coinfected with TB and HIV can be improved with simultaneous treatment of both diseases, [21] [22] [23] but few studies (small cohort studies and case series) describe treatment outcomes of coinfected pediatric patients. 10, [24] [25] [26] [27] Previous studies have demonstrated that mortality among children with DR TB in South Africa differs by province (12%-31%), but overall treatment success rates (70%-83%) can be similar to, if not better than, those seen in adults. [28] [29] [30] The objective of this analysis was to assess the association between treatment outcomes with HIV status and other risk factors among children and adolescents with MDR TB.
METHODS

Ethics
Ethics approval for this project was obtained from the South African National Department of Health, each provincial Department of Health, the City of Johannesburg and all participating hospitals. Institutional Review Board approval was obtained from the South African Medical Research Council Ethics Committee and the Human Research Ethics Committee of University of the Witwatersrand in Johannesburg. This project was reviewed by the Centers for Disease Control and Prevention, Atlanta, GA and determined to be routine disease surveillance.
Data Collection
The setting and data collection process for this analysis have been previously described. 29 Briefly, this was a retrospective cohort study of abstracted data from the records of all children (<13 years)
Definitions
We used standard anti-TB drug resistance category definitions for INH and rifampicin monoresistance, polyresistance, MDR and extensive drug resistance (XDR). 31 Pre-extensively drug-resistant TB (Pre-XDR TB) was defined as MDR TB plus resistance to any fluoroquinolone or second-line injectable drug (capreomycin, kanamycin or amikacin), but not both.
A DR TB treatment regimen was defined as any TB treatment regimen that differed from standard first-line therapy and was started after registration at a MDR TB hospital. World Health Organization (WHO) recommends that MDR TB treatment regimens include at least 4 effective second-line anti-TB drugs, including a fluoroquinolone and second-line injectable drug. 32 For the time period during which this cohort was diagnosed and treated, there were no standard national guidelines for treatment of DR TB in children in South Africa.
Weight-for-age Z scores were calculated as a marker of malnutrition. Underweight was defined according to WHO definition as below 2 standard deviations below the mean. Severely underweight was defined as below 3 standard deviations below the mean. Standard WHO definitions for MDR TB treatment outcome were used: cure/complete, died, failed, lost to follow-up, unknown/on treatment/transfer. 33 Death was the outcome of interest for the survival analysis.
Statistical Methods
Data were analyzed using SAS 9.4 (SAS Institute, Cary, NC). This analysis was limited to participants diagnosed before 2009 (to allow time to ascertain treatment outcome) with a documented HIV status and treatment outcome. Observations from Limpopo province were excluded because of the small number of participants (n = 5) from that province that were diagnosed before 2009. The very small number of participants with INH monoresistance or polyresistance were excluded from the analysis of outcomes to satisfy convergence criteria. Participants with monoresistance to rifampicin were included with the MDR participants. Frequencies and proportions were reported for all categorical variables. Pearson χ 2 test, Fisher exact test or Wilcoxon-Mann-Whitney tests were used to assess bivariate associations of categorical variables of interest with HIV status. An alpha of 0.05 was used to test the statistical significance of all associations.
To assess the effect of HIV infection on the rate of poor outcomes, a time-to-event analysis was conducted. The event of interest was death. Participants contributed person-time from the start of DR TB treatment (T 0 ) until the date of event or the date they were censored (T 1 ). Participants who were cured, completed treatment or failed treatment were censored on the date they reached their treatment outcome. Participants who were still on treatment, transferred or were lost to follow-up were censored on the last date of contact. Participants who had not experienced the event of interest after 2 years of follow-up were censored at 730.5 days. Those who were not on treatment for at least 15 days (T 1 − T 0 < 15) were excluded from the survival analysis.
Variables of interest (HIV status, sex, age, province, year of TB diagnosis, resistance profile, presence of extra pulmonary TB and weight status) were first assessed independently using the Kaplan-Meier method and log-rank tests. To calculate hazard ratios and corresponding confidence intervals as a measure of effect, statistically significant variables (and variables that are known to influence survival) were considered for inclusion in bivariate and multivariable Cox proportional hazard models.
The proportional hazard assumption was assessed visually win unadjusted -ln-ln curves and tested statistically by looking at the significance of time-dependent covariates and goodness of fit methods that assess the correlation between Schoenfeld residuals and ranked failure times. To satisfy the proportional hazards assumption for the time-to-event analysis, age was collapsed into a dichotomous variable indicating 0-7 years old and 8-17 years old. Pre-XDR TB and XDR TB were also collapsed to create a dichotomized variable that indicated Pre-XDR/XDR TB versus MDR TB. Cox proportional hazard bivariate models were fit with each individual predictor that did not violate the proportional hazards assumption. Variables that were significant in the bivariate models were then included in the multivariable analysis. A Cox proportional hazards model, stratified on province and year of diagnosis, was fit to determine adjusted hazard ratios (aHR).
RESULTS
Demographic and Clinical Information
There were 774 eligible children and adolescents diagnosed with DR TB at MDR TB hospitals in the 4 areas. A total of 423 were eligible for this analysis and slightly more than half (n = 238, 56%) were HIV infected (Table, Supplemental Digital Content 1, http://links.lww.com/INF/C769). Culture results were available for 419 (99.1%) participants, 398 (95.0%) of which were positive. The majority of participants were cared for in KwaZulu-Natal (n = 252, 59.6%), had a median age of 10.7 years (interquartile range: 5.5-15.3) and less than half were male (n = 177, 41.9%). Age differed by HIV status (P < 0.001), with HIV-uninfected participants tending to be older than HIV-infected patients. More HIV-infected participants were male (47.7%) than HIV-negative participants (34.6%; P = 0.007). A significantly higher proportion of HIV-infected participants were severely underweight compared with those who were HIV uninfected (n = 86, 38.7% vs. n = 30, 17.1%; P < 0.001).
Among participants with data on previous TB treatment history (n = 341), HIV-infected individuals were more likely to have been previously treated (58.7%) than HIV-negative participants (36.4%; P < 0.001). Among participants who had information about their contact history (n = 249), previous contact with an MDR/XDR TB case was higher among HIV-negative individuals, but this difference did not reach statistical significance (P = 0.08). There was no significant difference in the number of symptoms reported by HIV status (P = 0.6).
HIV-uninfected participants were more likely to have had a positive smear microscopy test (68.2%) compared with HIVinfected participants (59.2%), but this did not reach statistical significance (P = 0.06). There were 389 (92.0%) participants who had at least 1 chest radiograph and 378 (97.2%) were reported as abnormal. HIV-infected individuals were more likely to have extrapulmonary TB (32.9%) compared with individuals without HIV (9.1%; P < 0.001). There were 391 (92.4%) participants who had at least 1 drug susceptibility test recorded. There was no statistically significant difference in the distribution of resistance profiles by HIV status (P = 0.07).
Of the 238 HIV-infected participants, only 133 (55.9%) had at least 1 documented CD4 count, of which 52 (39.1%) had at least 1 CD4 count below 200. There were 162 (68.1%) HIV-infected participants who had a record of highly active antiretroviral therapy (ART) before or during the current TB episode and 142 (60.0%) who had record of co-trimoxazole preventive therapy.
There were 245 (57.9%) participants successfully treated (cure/complete), 69 (16.3%) died, 3 (0.7%) treatment failed, 36 (8.5%) were lost to follow-up and 70 (16.6%) were still on treatment, transferred or unknown. A significantly higher proportion of HIV-negative participants were cured or completed treatment than participants who were HIV infected (61.6% vs. 55.0%; P = 0.02). A higher proportion of HIV-infected participants (20.6% vs. 10.8% of HIV negative) died while on treatment.
Rate of Poor Treatment Outcomes
The Kaplan-Meier estimator indicated that time to death was significantly different by HIV status (P = 0.008), sex (P < 0.001), province (P = 0.045) and weight status (P = 0.002; Table 1 ). Year of TB diagnosis (P = 0.054) and age (P = 0.09) were close to being statistically different. Over the 2-year risk period, HIV-infected participants experienced an unadjusted hazard of death that was more than 2-fold higher than participants who were HIV uninfected [hazard ratio = 2.20; 95% confidence interval (CI): 1.22-3.97; Table 2 ; Fig. 1 ]. The multivariable Cox proportional hazard model was stratified on province and year of diagnosis and contained covariates for HIV status, sex, age and weight. There were 372 observations that contributed person-time to this risk set. Of those, 50 (13.4%) participants experienced death and 322 (86.6%) were censored. Over the 2-year risk period, the adjusted rate of death was over 2-fold higher among participants with HIV compared with participants who were HIV uninfected (aHR = 2.28; 95% CI: 1.11-4.68). Males (aHR = 2.69; 95% CI: 1.47-4.9) and participants who were underweight (aHR = 2.65; 95% CI: 1.37-5.13) also experienced significantly higher hazards of death.
DISCUSSION
This analysis of pediatric patients with DR TB describes the clinical presentation and treatment outcomes of those diagnosed in 3 of the eastern provinces of South Africa. These results indicate that favorable outcomes are achievable in pediatric MDR TB patients, with 57.9% of the participants in our cohort experiencing cure or treatment completion outcome. However, the rate of death was higher among children who were HIV infected, male or underweight. The treatment success rate in our cohort of children with DR TB was higher than the global treatment success rate for all MDR TB cases but lower than other published cohorts of pediatric MDR TB (refs: WHO global TB report 2015, hicks, seddon, isaadakis). This is, to our knowledge, the largest cohort of DR TB pediatric patients with HIV infection and TB treatment outcome described in the literature. Patients in the MDR TB hospitals were required to have culture confirmation before admission and initiation of treatment. As a result, this population of patients was more likely to have advanced disease. 11 Almost every child included in this cohort had a positive sputum culture and more than half were HIV infected.
Despite the severity of disease and high prevalence of coinfection, over half of our participants experienced favorable outcomes-treatment completion or cure. Individualized treatment regimens provided by experienced providers in a hospitalized setting has been shown to be successful in both adults and children with DR TB. 28, 34 However, HIV infection was associated with higher mortality and survival analysis indicated that HIV infection had an impact on mortality of children with DR TB. Overall, 9.7% of our cohort had XDR TB, which is very similar to adults in South Africa (10.5% XDR TB among MDR TB cases). 35 These results indicated that the proportion of children with XDR TB or Pre-XDR TB was lower among those infected with HIV. This may be because pediatric patients with HIV infection and pre-XDR or XDR TB did not live long enough to be admitted to treatment facilities that require culture confirmation, but a consistent association between HIV infection and XDR TB has not been documented. Primary drug resistance rather than acquired drug resistance is more common among children. Therefore, we think it unlikely that the pediatric patients acquired pre-XDR or XDR TB, but, rather, that these differences by HIV status could be related to differences in HIV infection and drug resistance transmission patterns in each region.
The occurrence of death in our cohort was relatively low when compared with adult patients with DR TB, 36 but these findings are similar to those from a previous study of 84 children with MDR TB in South Africa that reported 11% mortality. 36 This is likely, in part, related to prolonged hospitalization in facilities where providers are experienced in treating DR TB both with and without HIV infection. It is unclear why male pediatric patients were more likely to have poor outcomes. One hypothesis is that sociocultural factors may play a role, with families seeking care for boys at a later stage of disease than for girls. This was proposed by some of the caregivers at the largest MDR TB hospital in our cohort though we did not see significantly different weight or disease severity indicators for boys over girls. Similar to a previous study, although HIV infection was associated with shorter survival, malnutrition (based on weight-for-age Z score) was the most predictive of death.
36
Limitations
This study has important limitations resulting from retrospective data collection limited to available medical records and charts. In general, medical charts at the MDR TB hospitals were comprehensive though charting practices were inconsistent and variable across sites. Some data, such as contact history and history of ART, were often incomplete. When key data were unavailable in medical charts, they were obtained from laboratory and programmatic surveillance systems. Many of the HIV-infected patients did not have records of CD4 data or ART use. Therefore, we were unable to analyze the HIV-infected group by severity of HIV-related disease or by HIV treatment status. In our timeto-event analysis, about 25% of our participants had incomplete follow-up data (lost to follow-up, still on treatment, transferred or unknown). Finally, cause of death was not documented to a level of detail that could have enabled us to understand the influence of opportunistic infections (other than TB) on survival. Because we reviewed pediatric patients treated at MDR TB facilities, our findings are not generalizable to all children and adolescents with DR TB. More data from a variety of settings are needed to better understand true morbidity and mortality of all pediatric patients with DR TB.
CONCLUSION
The analysis of treatment outcomes among this large cohort of DR TB pediatric patients with HIV infection demonstrates that favorable outcomes are achievable. Although these patients were treated at MDR TB facilities by experienced clinicians, expertise and availability of medications to build effective regimens are improving. Based on history of previous treatment and contact to DR TB patients, there are opportunities for earlier diagnosis and treatment to improve outcomes for pediatric patients with DR TB. Renewed focus on early treatment with medications effective against resistant TB, life-saving ART and nutritional rehabilitation will serve to improve outcomes among the most vulnerable of those affected by TB.
